Annual report pursuant to Section 13 and 15(d)

Note 2 - Acquisitions - Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details)

v3.7.0.1
Note 2 - Acquisitions - Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jul. 08, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Intangible Assets:        
Goodwill   $ 579,026 $ 430,882 $ 390,638
Cash paid, net of cash acquired   253,785 91,423 $ 420,102
Contingent consideration payable   3,300 $ 38,500  
Zephyrus [Member]        
Current assets, net of cash   56    
Equipment   32    
Other long-term assets      
Intangible Assets:        
Goodwill   8,686    
Total assets acquired   17,074    
Liabilities   54    
Deferred income taxes, net   2,521    
Net assets   14,500    
Less fair-value of previous investment      
Net assets acquired   14,500    
Cash paid, net of cash acquired   8,000    
Business Combination, Consideration Transferred, Liabilities Incurred      
Contingent consideration payable   6,500    
Net purchase price   14,500    
Zephyrus [Member] | Developed Technology Rights [Member]        
Intangible Assets:        
Intangible assets   8,300    
Zephyrus [Member] | Trade Names [Member]        
Intangible Assets:        
Intangible assets      
Zephyrus [Member] | Customer Relationships [Member]        
Intangible Assets:        
Intangible assets      
Zephyrus [Member] | Noncompete Agreements [Member]        
Intangible Assets:        
Intangible assets      
Cliniqa [Member]        
Current assets, net of cash   11,926    
Equipment   1,436    
Other long-term assets   58    
Intangible Assets:        
Goodwill   42,669    
Total assets acquired   102,189    
Liabilities   1,508    
Deferred income taxes, net   17,793    
Net assets   82,888    
Less fair-value of previous investment      
Net assets acquired   82,888    
Cash paid, net of cash acquired $ 82,900 82,888    
Business Combination, Consideration Transferred, Liabilities Incurred      
Contingent consideration payable      
Net purchase price   82,888    
Cliniqa [Member] | Developed Technology Rights [Member]        
Intangible Assets:        
Intangible assets   18,000    
Cliniqa [Member] | Trade Names [Member]        
Intangible Assets:        
Intangible assets   1,100    
Cliniqa [Member] | Customer Relationships [Member]        
Intangible Assets:        
Intangible assets   27,000    
Cliniqa [Member] | Noncompete Agreements [Member]        
Intangible Assets:        
Intangible assets      
Novus Holdings, LLC [Member]        
Deferred income taxes, net   (438)    
Current assets, net of cash   1,206    
Equipment   971    
Other long-term assets   19    
Intangible Assets:        
Goodwill   91,658    
Total assets acquired   114,754    
Liabilities   1,965    
Net assets   113,227    
Less fair-value of previous investment   18,300    
Net assets acquired   94,927    
Cash paid, net of cash acquired   59,927    
Business Combination, Consideration Transferred, Liabilities Incurred      
Contingent consideration payable   35,000    
Net purchase price   94,927    
Novus Holdings, LLC [Member] | Developed Technology Rights [Member]        
Intangible Assets:        
Intangible assets   20,200    
Novus Holdings, LLC [Member] | Trade Names [Member]        
Intangible Assets:        
Intangible assets   100    
Novus Holdings, LLC [Member] | Customer Relationships [Member]        
Intangible Assets:        
Intangible assets   600    
Novus Holdings, LLC [Member] | Noncompete Agreements [Member]        
Intangible Assets:        
Intangible assets      
ProteinSimple [Member]        
Current assets, net of cash   19,660    
Equipment   1,983    
Other long-term assets   554    
Intangible Assets:        
Goodwill   134,074    
Total assets acquired   333,371    
Liabilities   11,644    
Deferred income taxes, net   21,674    
Net assets   300,053    
Less fair-value of previous investment      
Net assets acquired   300,053    
Cash paid, net of cash acquired   300,053    
Business Combination, Consideration Transferred, Liabilities Incurred      
Contingent consideration payable      
Net purchase price   300,053    
ProteinSimple [Member] | Developed Technology Rights [Member]        
Intangible Assets:        
Intangible assets   39,200    
ProteinSimple [Member] | Trade Names [Member]        
Intangible Assets:        
Intangible assets   36,100    
ProteinSimple [Member] | Customer Relationships [Member]        
Intangible Assets:        
Intangible assets   101,600    
ProteinSimple [Member] | Noncompete Agreements [Member]        
Intangible Assets:        
Intangible assets   200    
CyVek, Inc. [Member]        
Current assets, net of cash   10,739    
Equipment   1,266    
Other long-term assets   40    
Intangible Assets:        
Goodwill   28,408    
Total assets acquired   65,163    
Liabilities   2,166    
Deferred income taxes, net   2,875    
Net assets   60,122    
Less fair-value of previous investment      
Net assets acquired   60,122    
Cash paid, net of cash acquired   60,122    
Business Combination, Consideration Transferred, Liabilities Incurred      
Contingent consideration payable      
Net purchase price   60,122    
CyVek, Inc. [Member] | Developed Technology Rights [Member]        
Intangible Assets:        
Intangible assets   5,010    
CyVek, Inc. [Member] | Trade Names [Member]        
Intangible Assets:        
Intangible assets   5,300    
CyVek, Inc. [Member] | Customer Relationships [Member]        
Intangible Assets:        
Intangible assets   14,400    
CyVek, Inc. [Member] | Noncompete Agreements [Member]        
Intangible Assets:        
Intangible assets